NBIX News and Press, Neurocrine Biosciences Inc. From 05/10/22

The decision by Pfizer (NYSE:PFE) to acquire the commercial-stage biopharma company, Biohaven Pharmaceutical (BHVN) for nearly $12 billion has revived the beaten-down biotech space on Tuesday. SPDR S&P Biotech ETF (XBI) is trading higher after three sessions of declines to record the...

The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Neurocrine Biosciences, Inc. 2022 Q1 - Results - Earnings Call Presentation

Image source: The Motley Fool. Neurocrine Biosciences (NASDAQ: NBIX) Q1 2022 Earnings Call May 04, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Neurocrine Biosciences (NBIX) Q1 2022 Earnings Call Transcript

Neurocrine Biosciences, Inc. (NBIX) Q1 2022 Earnings Conference Call May 04, 2022, 08:00 ET Company Participants Todd Tushla - VP, IR Kevin Gorman - CEO & Director Matthew Abernethy - CFO Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer Kyle Gano - Chief Busin...

Neurocrine Biosciences press release (NASDAQ:NBIX): Q1 Non-GAAP EPS of $0.30 misses by $0.29. Revenue of $310.6M (+31.3% Y/Y) beats by $6.53M. At March 31, 2022, the Company had cash, cash equivalents and marketable securities of $1.2 billion.  Reiterated 2022 INGREZZA Sales and Operatin...

Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance PR Newswire INGREZZA ® (valbenazine) First Quarter Net Product Sales of $303 Million INGREZZA ® (valbenazine) 2022 Net Product...

Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference PR Newswire SAN DIEGO , May 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2022 Healthc...

Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is $0.59 (+20.4% Y/Y) and the consensus Revenue Estimate is $304.07M (+28.5% Y/Y). Over the last 2 years, NBIX has beaten EPS estimates 38% o...

ABC,AMRN,AMRX,ASC,ATI,AVA,AVNS,BDC,BIP,BLX,BRKR,BRY,BWA,CDW,CFMS,CGAU,CLDT,CLH,CLVS,CMLS,CRL,CRTO,CSII,CVS,DCPH,DIN,DOC,OTCPK:EADSF,EAT,EDIT,EMR,OTCPK:ENLAY,EXPI,EYPT,FDP,FMS,OTCPK:FSNUF,FTS,FUN,GEL,GNRC,GOLD,GTHX,HZNP,IDXX,IMKTA,INSW,IONS,ISEE,JCI,JHG,OTCPK:LBLCF,LITE,LL,LNG,MAR,MCRB,MFA,MIR...

Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week PR Newswire States Across the Country Declare First Week of May (1-7) Tardive Dyskinesia Awareness Week to Raise Awareness of This Burdensome and Of...